Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S (now Evaxion A/S) covers the month of May 2025. The report details the resolutions passed at the Annual General Meeting (AGM) held on April 30, 2025. The filing serves to incorporate these corporate governance actions by reference into the Company's registration statements.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. The document confirms that the audited annual report for the financial year 2024 was approved and that the loss for 2024 was transferred to the next financial year, but no specific loss amount is disclosed in this text.
Material Changes
- Corporate Name Change: The Company's primary name was changed from "Evaxion Biotech A/S" to "Evaxion A/S". "Evaxion Biotech A/S" and "NovVac A/S" were adopted as secondary names.
- Board Composition: Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda were re-elected. Helen Tayton-Martin was elected as a new board member.
- Capital Authorization: Shareholders authorized the Board to issue warrants and increase share capital without pre-emptive rights up to a nominal value of DKK 100,000,000 for each authorization.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking financial guidance, revenue outlook, or management commentary regarding operational performance. The primary focus is on corporate governance and capital structure flexibility.
Key Resolutions and Contingencies
- Warrant Issuance: The Board is authorized until April 15, 2029, to issue warrants to investors, lenders, and advisors. Exercise prices may be set at market price or a discount.
- Share Capital Increase: The Board is authorized until May 1, 2027, to increase share capital by up to DKK 100,000,000 via cash contributions, potentially at a discount to the listed price of ADSs.
- Auditor: EY Godkendt Revisionspartnerselskab was re-elected as the Company's auditor.
Investor Verification Checklist
- Verify the exact number of shares outstanding to calculate the potential dilution impact of the DKK 100,000,000 warrant and share capital authorizations.
- Review the full audited annual report for 2024 to determine the specific magnitude of the loss transferred to the next financial year.
- Monitor future filings for the actual issuance of warrants or shares under the new authorizations and the pricing terms applied.
- Confirm the updated ticker symbol or trading name if the change from "Evaxion Biotech A/S" to "Evaxion A/S" affects market data feeds.